Trial Profile
S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Mercaptopurine (Primary) ; Methotrexate (Primary) ; Tretinoin (Primary)
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 14 Apr 2016 Status changed from active, no longer recruiting to completed.
- 26 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 17 Jan 2014 Planned End Date changed from 1 Sep 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov record .